228 related articles for article (PubMed ID: 23376848)
1. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
2. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
3. Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma.
Wong CC; Wong CM; Ko FC; Chan LK; Ching YP; Yam JW; Ng IO
PLoS One; 2008 Jul; 3(7):e2779. PubMed ID: 18648664
[TBL] [Abstract][Full Text] [Related]
4. DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity.
Tripathi V; Popescu NC; Zimonjic DB
Mol Cell Biol; 2012 Jun; 32(11):2145-59. PubMed ID: 22473989
[TBL] [Abstract][Full Text] [Related]
5. GAP-independent functions of DLC1 in metastasis.
Barras D; Widmann C
Cancer Metastasis Rev; 2014 Mar; 33(1):87-100. PubMed ID: 24338004
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis.
Qin Y; Chu B; Gong W; Wang J; Tang Z; Shen J; Quan Z
J Gastroenterol Hepatol; 2014 May; 29(5):964-72. PubMed ID: 24329682
[TBL] [Abstract][Full Text] [Related]
7. RhoA/ROCK and Cdc42 regulate cell-cell contact and N-cadherin protein level during neurodetermination of P19 embryonal stem cells.
Laplante I; Béliveau R; Paquin J
J Neurobiol; 2004 Sep; 60(3):289-307. PubMed ID: 15281068
[TBL] [Abstract][Full Text] [Related]
8. FKBP51 regulates cell motility and invasion via RhoA signaling.
Takaoka M; Ito S; Miki Y; Nakanishi A
Cancer Sci; 2017 Mar; 108(3):380-389. PubMed ID: 28032931
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy.
Guan M; Tripathi V; Zhou X; Popescu NC
Cancer Gene Ther; 2008 Jun; 15(6):371-81. PubMed ID: 18369381
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function.
Jensch A; Frey Y; Bitschar K; Weber P; Schmid S; Hausser A; Olayioye MA; Radde NE
J Biol Chem; 2018 Sep; 293(37):14407-14416. PubMed ID: 30045871
[TBL] [Abstract][Full Text] [Related]
12. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.
Chung GE; Yoon JH; Lee JH; Kim HY; Myung SJ; Yu SJ; Lee SH; Lee SM; Kim YJ; Lee HS
Oncol Rep; 2011 Jun; 25(6):1739-46. PubMed ID: 21455586
[TBL] [Abstract][Full Text] [Related]
14. Flavone inhibits migration through DLC1/RhoA pathway by decreasing ROS generation in breast cancer cells.
Zhu W; Ma L; Yang B; Zheng Z; Chai R; Liu T; Liu Z; Song T; Li F; Li G
In Vitro Cell Dev Biol Anim; 2016 May; 52(5):589-97. PubMed ID: 26935193
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.
Scholz RP; Gustafsson JO; Hoffmann P; Jaiswal M; Ahmadian MR; Eisler SA; Erlmann P; Schmid S; Hausser A; Olayioye MA
Exp Cell Res; 2011 Feb; 317(4):496-503. PubMed ID: 21087603
[TBL] [Abstract][Full Text] [Related]
16. StarD13 differentially regulates migration and invasion in prostate cancer cells.
Jaafar L; Fakhoury I; Saab S; El-Hajjar L; Abou-Kheir W; El-Sibai M
Hum Cell; 2021 Mar; 34(2):607-623. PubMed ID: 33420961
[TBL] [Abstract][Full Text] [Related]
17. DLC1 negatively regulates angiogenesis in a paracrine fashion.
Shih YP; Liao YC; Lin Y; Lo SH
Cancer Res; 2010 Nov; 70(21):8270-5. PubMed ID: 20861185
[TBL] [Abstract][Full Text] [Related]
18. DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling.
Scholz RP; Regner J; Theil A; Erlmann P; Holeiter G; Jähne R; Schmid S; Hausser A; Olayioye MA
J Cell Sci; 2009 Jan; 122(Pt 1):92-102. PubMed ID: 19066281
[TBL] [Abstract][Full Text] [Related]
19. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.
Kim TY; Jackson S; Xiong Y; Whitsett TG; Lobello JR; Weiss GJ; Tran NL; Bang YJ; Der CJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16868-73. PubMed ID: 24082123
[TBL] [Abstract][Full Text] [Related]
20. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
